New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 50.1mg equivalent to 37.5mg sunitinib;   - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to 37.5mg sunitinib   excipient: croscarmellose sodium gelatin ink iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 50.1mg equivalent to sunitinib 37.5mg;   - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to sunitinib 37.5mg   excipient: croscarmellose sodium gelatin ink iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - sunitinib malate 50.1mg equivalent to sunitinib 37.5 mg - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to sunitinib 37.5 mg excipient: croscarmellose sodium gelatin iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide water - treatment of advanced renal cell carcinoma treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net)

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 16.7mg equivalent to 12.5 mg sunitinib;   - capsule - 12.5 mg - active: sunitinib malate 16.7mg equivalent to 12.5 mg sunitinib   excipient: croscarmellose sodium gelatin iron oxide red magnesium stearate mannitol povidone propylene glycol shellac sodium hydroxide sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - sunitinib malate 50.100mg eqv sunitinib - capsule - 37.5mg - sunitinib malate 50.100mg eqv sunitinib 37.5mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 50.1 mg (equivalent: sunitinib, qty 37.5 mg) - capsule - excipient ingredients: propylene glycol; iron oxide black; isopropyl alcohol; butan-1-ol; ammonia; ethanol absolute; titanium dioxide; povidone; purified water; potassium hydroxide; mannitol; shellac; croscarmellose sodium; iron oxide yellow; magnesium stearate; sodium lauryl sulfate; gelatin - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Canada - English - Health Canada

taro pharmaceuticals inc - sunitinib (sunitinib malate) - capsule - 37.5mg - sunitinib (sunitinib malate) 37.5mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 50.1 mg (equivalent: sunitinib, qty 37.5 mg) - capsule - excipient ingredients: sodium lauryl sulfate; ethanol absolute; ammonia; butan-1-ol; iron oxide yellow; croscarmellose sodium; potassium hydroxide; mannitol; povidone; shellac; purified water; iron oxide black; titanium dioxide; propylene glycol; isopropyl alcohol; magnesium stearate; gelatin - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Canada - English - Health Canada

teva canada limited - sunitinib (sunitinib malate) - capsule - 25mg - sunitinib (sunitinib malate) 25mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 33.4mg equivalent to sunitinib 25mg;   - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to sunitinib 25mg   excipient: croscarmellose sodium gelatin ink iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma